WHO Guidelines on GLP-1 Drugs for Weight Loss
Context:
The World Health Organization (WHO) has issued its first global guidelines supporting the use of Glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults
What are GLP-1 Drugs?
They are originally used for Type 2 diabetes.
These drugs have revolutionized obesity treatment by effecting significant weight loss and offering metabolic benefits.
Currently, there are 12 approved GLP-1 therapies
Key Guidelines:
The WHO recommends GLP-1 drugs for long-term treatment in adults (excluding pregnant women).
However, the recommendation is conditional due to high costs and limited data on long-term safety and efficacy after discontinuation.
The guidelines emphasize that medication alone is insufficient.
Intensive behavioural interventions (diet and physical activity) must continue alongside the drugs.
The guidelines explicitly recognize obesity as a chronic disease requiring lifetime care shifting away from viewing it merely as a lifestyle issue.
Challenges:
Equitable Access:
High costs and limited supply are major barriers.
Current production capacity can cover only ~100 million people (less than 10% of need).
Global Impact:
With the global cost of obesity predicted to reach $3 trillion annually by 2030, the WHO suggests manufacturing generics and including these drugs in the essential medicines list to ensure wider access.